1 |
Bogaards, J. J, Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J. and van Bladeren, P. J. (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 30, 1131-1152.
DOI
|
2 |
Buckley, M. M. T., Grant, S. M., Goa, K. L., McTabish, D. and Sorkin, E. M. (1990) Diltiazem: A reappraisal of its pharmacological properties and therapeutic use. Drugs 39, 757-806.
DOI
|
3 |
Buur, T., Larsson, R., Berglund, U., Donat, F. D. V. M. and Tronquet, C. (1997) Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J. Clin. Pharmacol. 37, 108-115.
DOI
ScienceOn
|
4 |
Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P. and Shin, H. C. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686.
DOI
|
5 |
Chaffman, M. and Brogden, R. N. (1985). Diltiazem: a review of its pharmacological properties and therapeutic effi cacy. Drugs 29, 387-454.
DOI
|
6 |
Chiou, W. L. (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J. Pharmacokinet. Biopharm. 6, 539-546.
DOI
|
7 |
Choi, J. S., Piao, Y. J. and Han, H. K. (2006) Pharmacokinetic interaction between fl uvastatin and diltiazem in rats. Biopharm. Drug Disposition 27, 437-441.
DOI
ScienceOn
|
8 |
Crespi, C. L., Miller, V. P. and Penman, B. W. (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190.
DOI
|
9 |
Wacher, V. J., Salphati, L. and Benet, L. Z. (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46, 89-102.
DOI
|
10 |
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S. (1987) Identifi cation of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029-1036.
DOI
|
11 |
Yusa, K. and Tsuruo, T. (1989). Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specifi c sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006.
|
12 |
Weir, M. R. (1995) Diltiazem: ten years of clinical experience in the treatment of hypertension. J. Clin. Pharmacol. 35, 220-232.
DOI
ScienceOn
|
13 |
Yeung, P. K., Feng, J. D. Z. and Buckley, S. J. (1998) Pharmacokinetics and hypotensive effect of diltiazem in rabbits: Comparison of diltiazem with its major metabolites. J. Pharm. Pharmacol. 50, 1247-1253.
DOI
|
14 |
Yeung, P. K., Prescott, C., Haddad, C., Montague, T. J., McGregor, C., Quilliam, M. A., Xei, M., Li, R., Farmer, P. and Klassen, G. A. (1993) Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur. J. Drug Metab. Pharmacokinet. 18, 199-206.
DOI
|
15 |
Lefebvre, M., Homsy, W., Caille, G. and du Souich, P. (1996) Firstpass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. Pharm. Res. 13, 124-128.
DOI
|
16 |
Lewis, D. F. V. (1996) Cytochrome P450. Substrate specifi city and metabolism. In Cytochromes P450. Structure, Function, and Mechanism, pp.122-123. Taylor & Francis, Bristol.
|
17 |
Shah, J., Fratis, A., Ellis, D., Murakami, S. and Teitelbaum, P. (1990) Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J. Clin. Pharmacol. 30, 733-736.
DOI
|
18 |
Narita, H., Otsuka, M., Yabana, H. and Nagao, T. (1986) Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration. J. Pharmacobiodyn. 9, 547-553.
DOI
|
19 |
Pichard, L., Gillet, G., Fabre, I., Dalet-Beluche, I., Bonfi ls, C., Thenot, J. P. and Maurel, P. (1990) Identifi cation of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the Ndemethylation of diltiazem. Drug Metab. Dispos. 18, 711-719.
|
20 |
Saltiel, E. and Ward, A. (1987) Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics effi cacy in platelet-dependent disease states. Drugs 34, 222-262.
DOI
|
21 |
Solomon, D. H. and Hart, R. G. (1994) Antithrombotic therapies for stroke prevention. Curr. Opin. Neurol. 7, 48-53.
DOI
|
22 |
Verhaeghe, R. (1991) Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 42, 51-57.
|
23 |
Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322-1330.
DOI
|
24 |
Homsy, W., Lefebvre, M., Caille, G. and du Souich, P. (1995b) Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. Pharm. Res. 12, 609-614.
DOI
|
25 |
Hong, S. P., Chang, K. S., Choi, D. H. and Choi, J. S. (2007) Effects of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Arch Pharm Res. 30, 90-95.
DOI
|
26 |
Kelly, P. A., Wang, H., Napoli, K. L., Kahan, B. D. and Strobel, H. W. (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet. 24, 321-328.
DOI
|
27 |
Ito, K., Kusuhara, H. and Sugiyama, Y. (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225-231.
DOI
|
28 |
Ito, M. K., Smith, A. R. and Lee, M. L. (1992) Ticlopidine: a new platelet aggregation inhibitors. Clin. Pharm. 11, 603-617.
|
29 |
Janzon, L., Bergqvist, D., Boberg, J., Boberg, M., Eriksson, I. and Lindgarde, F. (1990) Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227, 301-308.
DOI
|
30 |
Ko, J. W., Desta, Z., Soukhova, N. V., Tracy, T. and Flockhart, D. A. (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br. J. Clin. Pharmacol. 49, 343-351.
|
31 |
Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O., Schuetz, J., Wrighton, S. A. and Watkins, P. B. (1992) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186-1198.
|
32 |
Lee, Y. H., Lee, M. H. and Shim, C. K. (1991) Pharmacokinetics of diltiazem and deacetyldiltiazem in rats. Int. J. Pharm. 76, 71-76.
DOI
|
33 |
Gan, L. S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker. D. R. (1996) CYP3A-Like cytochrome P450-mediated metabolism and polarized effl ux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344-349.
|
34 |
Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T. and Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
|
35 |
Gent, M., Blakely, J. A., Easton, J. D., Ellis, D. J., Hachinski, V. C. and Harbison, J. W. (1989). The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1, 1215-1220.
|
36 |
Gidal, B. E., Sorkness, C. A., McGill, K. A., Larson, R. and Levine, R. R. (1995) Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther. Drug Monit. 17, 33-38.
DOI
|
37 |
Goebel, K. J. and Kolle, E. U. (1985) High performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J. Chromatogr. 345, 355-363.
DOI
|
38 |
Hass, W. K., Easton, J. D., Adams, H. P., Pryse-Phillips, W., Molony, B. A. and Anderson, S. (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in highrisk patients. N. Engl. J. Med. 321, 501-507.
DOI
|
39 |
Haynes, R. B., Sandler, R. S., Larson, E. B., Pater, J. L. and Yatsu, F. M. (1998) A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch. Intern. Med. 152, 1376-1380.
|
40 |
Homsy, W., Caille, G. and du Souich, P. (1995a) The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12, 1722-1726.
DOI
|